| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034669915 |
| P356 | DOI | 10.1038/SJ.ONC.1207691 |
| P3181 | OpenCitations bibliographic resource ID | 4839391 |
| P698 | PubMed publication ID | 15064724 |
| P5875 | ResearchGate publication ID | 8636347 |
| P2093 | author name string | Laura S Schmidt | |
| Bruno Streit | |||
| Anthony R Howlett | |||
| Christine Heigl | |||
| Congxin Liang | |||
| Daniel Candinas | |||
| Daniel M Aebersold | |||
| Deborah Stroka | |||
| Denise Stalder | |||
| Guenther Gruber | |||
| Kenneth E Lipson | |||
| Richard H Greiner | |||
| Sylvie Berthou | |||
| Yitzhak Zimmer | |||
| P2860 | cites work | Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies | Q42828980 |
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study | Q43797374 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. | Q44373949 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Different point mutations in the met oncogene elicit distinct biological properties. | Q53413979 | ||
| Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 | ||
| Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a | Q24647566 | ||
| Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors | Q27737008 | ||
| Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition | Q28212407 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop | Q34075619 | ||
| Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib | Q34191711 | ||
| Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. | Q34314967 | ||
| Dysregulation of Met receptor tyrosine kinase activity in invasive tumors | Q34584046 | ||
| Activating mutations for the met tyrosine kinase receptor in human cancer | Q36595980 | ||
| Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth | Q36734562 | ||
| The mutationally activated Met receptor mediates motility and metastasis | Q36735738 | ||
| Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx | Q38450015 | ||
| A novel germ line juxtamembrane Met mutation in human gastric cancer | Q40847293 | ||
| Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. | Q41106491 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5387-93 | |
| P577 | publication date | 2004-07-08 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants | |
| P478 | volume | 23 |
| Q34044173 | (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells |
| Q36777999 | A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met |
| Q24546366 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity |
| Q37705080 | Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele |
| Q35091523 | Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials |
| Q33588267 | An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis |
| Q37138521 | Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q34002709 | Cancer driver mutations in protein kinase genes |
| Q36481954 | Cancer genes in lung cancer: racial disparities: are there any? |
| Q39684133 | Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. |
| Q40220734 | Chemokines induce axon outgrowth downstream of Hepatocyte Growth Factor and TCF/β-catenin signaling |
| Q42093061 | Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma |
| Q39096429 | Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration |
| Q38846152 | Complementary PTM Profiling of Drug Response in Human Gastric Carcinoma by Immunoaffinity and IMAC Methods with Total Proteome Analysis |
| Q30374663 | Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. |
| Q40063867 | Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines |
| Q36868117 | DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma. |
| Q36828327 | Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1. |
| Q37263981 | Decorin is a novel antagonistic ligand of the Met receptor |
| Q38912279 | Development of antibody-based c-Met inhibitors for targeted cancer therapy |
| Q54295790 | Differential regulation of axonal growth and neuromuscular junction assembly by HGF/c-Met signaling. |
| Q37231567 | Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q33756853 | EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. |
| Q37399540 | Ethnic differences and functional analysis of MET mutations in lung cancer |
| Q35030073 | Fragment-based strategy for structural optimization in combination with 3D-QSAR. |
| Q24675200 | Genetic targeting of the kinase activity of the Met receptor in cancer cells |
| Q33737789 | Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles |
| Q34675956 | Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity |
| Q28509645 | Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases |
| Q33759272 | Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas |
| Q24645410 | Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma |
| Q36075407 | Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer |
| Q37363691 | In vivo cancer biomarkers of esophageal neoplasia |
| Q36526999 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. |
| Q38356393 | Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met |
| Q39236947 | Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors |
| Q36562316 | Isothiocyanatostilbenes as novel c-Met inhibitors |
| Q38880117 | KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. |
| Q38882892 | Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. |
| Q36953116 | Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis |
| Q34972637 | MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest |
| Q39365962 | MET in human cancer: germline and somatic mutations |
| Q39576714 | MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks |
| Q36245150 | MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor |
| Q37427292 | MET pathway as a therapeutic target |
| Q96230891 | MET-dependent solid tumours - molecular diagnosis and targeted therapy |
| Q27008925 | MET: a critical player in tumorigenesis and therapeutic target |
| Q93146625 | Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models |
| Q37183447 | Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities |
| Q35525305 | Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors |
| Q38445359 | NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants |
| Q46976409 | Oncogenic Met receptor induces ectopic structures in Xenopus embryos. |
| Q42276990 | Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer |
| Q33717395 | PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models |
| Q39665279 | Paracrine factors from fibroblast aggregates in a fibrin‐matrix carrier enhance keratinocyte viability and migration |
| Q41073453 | Prognostic Value of C-met Expression in Cholangiocarcinoma |
| Q35745037 | Retrospective Review of MET Gene Mutations |
| Q39428273 | Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma |
| Q33676726 | Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells |
| Q38090671 | Screening of liver-targeted drugs |
| Q37730020 | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers |
| Q33510934 | Sequence and structure signatures of cancer mutation hotspots in protein kinases |
| Q37437415 | Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities |
| Q34094632 | Small molecule c-Met kinase inhibitors: a review of recent patents |
| Q24307789 | Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase |
| Q37533648 | Targeted therapy for malignant glioma patients: lessons learned and the road ahead |
| Q38757070 | Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer |
| Q28513426 | Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation |
| Q36766188 | Targeting the HGF-cMET Axis in Hepatocellular Carcinoma |
| Q36142604 | Targeting the HGF/Met signalling pathway in cancer. |
| Q37792116 | Targeting the MET oncogene in cancer and metastases. |
| Q37331862 | Targeting the Met signaling pathway in renal cancer. |
| Q42811812 | The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models |
| Q34141913 | The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer |
| Q30494514 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma |
| Q30534479 | The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation |
| Q35563524 | The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis |
| Q28821187 | The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor |
| Q36158717 | Therapeutic targeting of receptor tyrosine kinases in lung cancer |
| Q39628107 | Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
| Q95815293 | c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma |
| Q42251074 | c-Met inhibition in a HOXA9/Meis1 model of CN-AML. |
| Q27649203 | c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations |
Search more.